DK2891490T3 - Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet - Google Patents

Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet Download PDF

Info

Publication number
DK2891490T3
DK2891490T3 DK13785891.6T DK13785891T DK2891490T3 DK 2891490 T3 DK2891490 T3 DK 2891490T3 DK 13785891 T DK13785891 T DK 13785891T DK 2891490 T3 DK2891490 T3 DK 2891490T3
Authority
DK
Denmark
Prior art keywords
beta
treatment
heart disease
left heart
adrenoceptor agonists
Prior art date
Application number
DK13785891.6T
Other languages
Danish (da)
English (en)
Inventor
Carulla Valentín Fuster
Ana García-Álvarez
Cabeza Borja Ibáñez
Original Assignee
Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii Cnic
Hospital Clinic Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii Cnic, Hospital Clinic Barcelona filed Critical Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii Cnic
Application granted granted Critical
Publication of DK2891490T3 publication Critical patent/DK2891490T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13785891.6T 2012-08-29 2013-08-28 Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet DK2891490T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
PCT/ES2013/070611 WO2014033343A1 (es) 2012-08-29 2013-08-28 Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Publications (1)

Publication Number Publication Date
DK2891490T3 true DK2891490T3 (da) 2021-03-15

Family

ID=47520452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13785891.6T DK2891490T3 (da) 2012-08-29 2013-08-28 Beta-3 adrenoceptor-agonister til behandlingen af pulmonal hypertension på grund af sygdom i venstre side af hjertet

Country Status (6)

Country Link
US (1) US10532038B2 (enExample)
EP (1) EP2891490B1 (enExample)
JP (1) JP6539206B2 (enExample)
DK (1) DK2891490T3 (enExample)
ES (2) ES2394349B1 (enExample)
WO (1) WO2014033343A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
CA3212587A1 (en) * 2021-03-31 2022-10-06 Jr. Raymond E. Stevens Compositions of micronized solabegron and methods of use
IT202300021417A1 (it) 2023-10-13 2025-04-13 Univ Pisa Agonisti o attivatori del recettore adrenergico beta-3

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006735B1 (en) 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DE3061334D1 (en) 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
EP0021636B1 (en) 1979-06-16 1982-12-01 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
ES8800842A1 (es) 1985-03-01 1987-12-01 Beecham Group Plc Un procedimiento para preparar una formulacion veterinariamente aceptable de ariletanolaminas promotora del crecimiento.
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
IT1204416B (it) 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ATE144139T1 (de) 1989-06-13 1996-11-15 Sanofi Sa Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
GB8925032D0 (en) 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
ATE185564T1 (de) 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
PT801059E (pt) 1994-11-29 2001-10-30 Dainippon Pharmaceutical Co Derivado indol
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ES2158996T3 (es) 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
CA2242351C (en) 1996-01-10 2003-03-11 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
BR9807096A (pt) 1997-01-28 2000-04-18 Merck & Co Inc Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica
ES2149742T1 (es) 1997-07-03 2000-11-16 Asahi Chemical Ind Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
WO2002006276A1 (en) 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US20040242485A1 (en) 2003-05-30 2004-12-02 Takashi Kadowaki Compositions and methods for the amelioration of leptin resistance
EP3459558B1 (en) * 2010-06-25 2020-07-29 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
CN102764438A (zh) 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途

Also Published As

Publication number Publication date
WO2014033343A9 (es) 2014-04-24
WO2014033343A1 (es) 2014-03-06
ES2394349B1 (es) 2013-11-04
EP2891490A1 (en) 2015-07-08
ES2394349A1 (es) 2013-01-30
ES2863749T3 (es) 2021-10-11
ES2394349A8 (es) 2013-04-25
EP2891490B1 (en) 2020-12-09
JP2015526497A (ja) 2015-09-10
JP6539206B2 (ja) 2019-07-03
US20150374655A1 (en) 2015-12-31
US10532038B2 (en) 2020-01-14

Similar Documents

Publication Publication Date Title
CY2023027I2 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
EP2673286A4 (en) THERAPEUTIC COMPOUNDS
BR112014001242A2 (pt) bomba cardíaca
EP2787837A4 (en) COMMONLY DECOMPOSED STABILIZER COMPOSITION
EP3636148C0 (en) PORTABLE HEART MONITOR
EP2863918A4 (en) SALT CRYSTALS
CO7030959A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO6791562A2 (es) Compuestos antivirales
DK3489226T3 (da) Hæmmere for natriumglucose-cotransporter 1
BR112014007781A2 (pt) compostos anti-virais
EP2822935A4 (en) INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
JP2013525366A5 (ja) ピリミジンジオン抗ウイルス性化合物
DK2734106T3 (da) Ekg-elektrodekonnektor
BR112013023934A2 (pt) bomba de tirar leite
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
EP2832740A4 (en) SALT OF 1- (2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL) CYTOSINE
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
DK3360869T3 (da) Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.
EP2709619A4 (en) COMPOUNDS FOR USE IN THE TREATMENT OF SACIAL SKIN INJECTION
DK2888010T3 (da) Fremgangsmåder til at hæmme fascin
DK2903432T3 (da) Fremgangsmåde til behandling af sædceller til kønsortering
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
BR302012006076S1 (pt) "configuração construtiva aplicada à barbatana"